RNA interference targeting human FAK and EGFR suppresses human non-small-cell lung cancer xenograft growth in nude mice

Cancer Gene Therapy

Volumn 20, Issue 2, 2013, Pages 101-108

  Li, C ^a   Zhang, X ^a   Cheng, L ^a   Dai, L ^a   Xu, F ^a   Zhang, J ^a   Tian, H ^a   Chen, X ^a   Shi, G ^a   Li, Y ^a   Du, T ^a   Zhang, S ^a   Wei, Y ^a   Deng, H ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

epidermal growth factor receptor; focal adhesion kinase; non small cell lung cancer cationic liposome; RNA interference

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE; PLASMID VECTOR; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; GENE SILENCING; HUMAN; IN VITRO STUDY; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; FOCAL ADHESION KINASE 1; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MICE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; MUS MUSCULUS;

EID: 84874105724     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.91     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Dempke WC, Suto T, Reck M. Targeted therapies for non-small cell lung cancer. Lung cancer 2010; 67: 257-274.
4. Novello S, Le Chevalier T. Chemotherapy for non-small-cell lung cancer. Part 1: early-stage disease. Oncology 2003; 17: 357-364.
5. Mazzocca A, Carloni V. The metastatic process: methodological advances and pharmacological challenges. Curr Med Chem 2009; 16: 1704-1717.
6. Kurenova E, Xu LH, Yang X, Baldwin Jr. AS, Craven RJ, Hanks SK et al. Focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor-interacting protein. Mol Cell Biol 2004; 24: 4361-4371.
7. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC. The role of focal-adhesion kinase in cancer-a new therapeutic opportunity. Nature reviews. Cancer 2005; 5: 505-515.
8. Kornberg LJ. Focal adhesion kinase and its potential involvement in tumor invasion and metastasis. Head Neck 1998; 20: 745-752.
9. Oktay MH, Oktay K, Hamele-Bena D, Buyuk A, Koss LG. Focal adhesion kinase as a marker of malignant phenotype in breast and cervical carcinomas. Hum Pathol 2003; 34: 240-245.
10. Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM et al. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol 2004; 165: 1087-1095.
11. Carelli S, Zadra G, Vaira V, Falleni M, Bottiglieri L, Nosotti M et al. Up-regulation of focal adhesion kinase in non-small cell lung cancer. Lung Cancer 2006; 53: 263-271.
12. Liu G, Meng X, Jin Y, Bai J, Zhao Y, Cui X et al. Inhibitory role of focal adhesion kinase on anoikis in the lung cancer cell A549. Cell Biol Int 2008; 32: 663-670.
13. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37: 3-8.
14. Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin Cancer Res 2001; 7: 1850-1855.
15. Nguyen DM, Schrump DS. Growth factor receptors as targets for lung cancer therapy. Semin Thorac Cardiovasc Surg 2004; 16: 3-12.
16. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169-181.
17. Hauck CR, Sieg DJ, Hsia DA, Loftus JC, Gaarde WA, Monia BP et al. Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factorstimulated signaling promoting the migration of invasive human carcinoma cells. Cancer Res 2001; 61: 7079-7090.
18. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2000; 2: 249-256.
19. Jones G, Machado Jr J, Merlo A. Loss of focal adhesion kinase (FAK) inhibits epidermal growth factor receptor-dependent migration and induces aggregation of nh(2)-terminal FAK in the nuclei of apoptotic glioblastoma cells. Cancer Res 2001; 61: 4978-4981.
20. Golubovskaya V, Beviglia L, Xu LH, Earp III HS, Craven R, Cance W. Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. J Biol Chem 2002; 277: 38978-38987.
21. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC. Prospects of RNA interference therapy for cancer. Gene Therapy 2006; 13: 464-477.
22. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004; 431: 371-378.
23. Halder J, Kamat AA, Landen J. CN, Han LY, Lutgendorf SK, Lin YG et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clinical Cancer Res 2006; 12: 4916-4924.
24. Smith K, Gunaratnam L, Morley M, Franovic A, Mekhail K, Lee S. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/-renal cancer. Cancer Res 2005; 65: 5221-5230.
25. Du XB, Lang JY, Xu JR, Lu Y, Wen YJ, Zhao JM et al. Vesicular stomatitis virus matrix protein gene enhances the antitumor effects of radiation via induction of apoptosis. Apoptosis 2008; 13: 1205-1214.
26. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
27. Raben D, Helfrich B, Bunn Jr PA. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys 2004; 59(Suppl): 27-38.
28. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeuticss. Nat Rev Drug Discov 2007; 6: 443-453.
29. Chen SM, Wang Y, Xiao BK, Tao ZZ. Effect of blocking VEGF, hTERT and Bcl-xl by multiple shRNA expression vectors on the human laryngeal squamous carcinoma xenograft in nude mice. Cancer Biol Ther 2008; 7: 734-739.
30. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M et al. RNA interferencedirected knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 2005; 280: 36529-36540.
31. Carelli S, Zadra G, Vaira V, Falleni M, Bottiglieri L, Nosotti M et al. Up-regulation of focal adhesion kinase in non-small cell lung cancer. Lung Cancer 2006; 53(3): 263-271.
32. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997; 3: 515-522.
33. Jiao X, Wang RY, Qiu Q, Alter HJ, Shih JW. Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes. J Gen Virol 2004; 85(Part 6): 1545-1553.
34. Sangare L, Morisset R, Omri A, Ravaoarinoro M. Incorporation rates, stabilities, cytotoxicities and release of liposomal tetracycline and doxycycline in human serum. J Antimicrob Chemother 1998; 42: 831-834.
35. Zelphati O, Szoka Jr FC. Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci USA 1996; 93: 11493-11498.
36. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelincholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 1995; 72: 896-904.
37. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995; 55: 3752-3756.
38. Simberg D, Weisman S, Talmon Y, Barenholz Y. DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. Crit Rev Ther Drug Carrier Syst 2004; 21: 257-317.
39. Yang Y, Bai Y, Xie G, Zhang N, Ma YP, Chen LJ et al. Efficient inhibition of nonsmall-cell lung cancer xenograft by systemic delivery of plasmid-encoding shorthairpin RNA targeting VEGF. Cancer Biother Radiopharm 2010; 25: 65-73.
40. Wan Y, Huang A, Yang Y, Xie G, Chen X, Hu J et al. A vector-based short hairpin RNA targeting Aurora A inhibits breast cancer growth. Int J Oncol 2010; 36: 1121-1128.
41. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol 1997; 15: 647-652.
42. Christensen CL, Gjetting T, Poulsen TT, Cramer F, Roth JA, Poulsen HS. Targeted cytosine deaminase-uracil phosphoribosyl transferase suicide gene therapy induces small cell lung cancer-specific cytotoxicity and tumor growth delay. Clinical Cancer Res 2010; 16: 2308-2319.
43. Lu C, Stewart D, Ji L, Ramesh R, Jayachandran G, Erasmus J et al. Systemic gene therapy with tumor suppressor FUS1-nanoparticles for recurrent/metastatic lung cancer. J Clin Oncol 2010; 28: 7582.
44. Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G et al. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS one 2012; 7: e34833.